Botanix Pharmaceuticals
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing it from being verifiable and neutral. (January 2021) |
| Type | Listed Public Company |
|---|---|
| ASX: BOT | |
| Industry | Biotechnology |
| Headquarters | Perth, Western Australia, and Philadelphia, USA |
Area served | Global |
Key people |
|
| Products | BTX 1503 | For the treatment of moderate to severe acne
BTX 1702 | For the treatment of rosacea BTX 1204A | For the treatment of moderate atopic dermatitis BTX 1801 | For use in a variety of antimicrobial applications |
| Website | www |
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company's lead product is Sofdra, which treats axillary hyperhidrosis[1]. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex,[2] for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.
Research
[edit]Botanix Pharmaceuticals' product pipeline[3] currently[when?] includes four programs for treatment of serious skin diseases:
Dermatology
- BTX 1503, for the treatment of moderate to severe acne
- BTX 1702, for the treatment of rosacea
- BTX 1204A, for the treatment of moderate atopic dermatitis
Antimicrobial
- BTX 1801, for use in a variety of antimicrobial applications
References
[edit]- ↑ "Products & Pipeline".
{{cite web}}: CS1 maint: url-status (link) - ↑ "Technology – Botanix Pharmaceuticals".
- ↑ "Pipeline – Botanix Pharmaceuticals".
